Inventor · disambiguated record
Scott L. Klakamp
Also filed as: KLAKAMP SCOTT · KLAKAMP SCOTT L
17 granted patents·3 pending applications·1,026 citations·filing 1995–2019
95Inventor score
Top patents by PatentIndex Score
20 records- 0197US7736644B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Jun 15, 2010·77 cites·115 claims
- 0297US7628986B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Dec 8, 2009·119 cites·83 claims
- 0397US5714166ABioactive and/or targeted dendrimer conjugatesDOW CHEMICAL CO·Filed 1995·Granted Feb 3, 1998·541 cites·136 claims
- 0496US7566772B2Antibodies against interleukin-1βAMGEN FREMONT INC·Filed 2006·Granted Jul 28, 2009·72 cites·19 claims
- 0595US7285269B2Antibodies directed to tumor necrosis factorAMGEN FREMONT INC·Filed 2003·Granted Oct 23, 2007·101 cites·35 claims
- 0694US7964193B2Antibodies against interleukin-1 βAMGEN FREMONT INC·Filed 2009·Granted Jun 21, 2011·29 cites·12 claims
- 0794US7585500B2Fully human monoclonal antibodies to IL-13AMGEN INC·Filed 2005·Granted Sep 8, 2009·36 cites·3 claims
- 0893US9096672B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofWEBER RICHARD·Filed 2009·Granted Aug 4, 2015·16 cites·38 claims
- 0988US9062113B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofWEBER RICHARD·Filed 2008·Granted Jun 23, 2015·7 cites·28 claims
- 1086US7994302B2Fully human monoclonal antibodies to IL-13AMGEN INC·Filed 2009·Granted Aug 9, 2011·8 cites·8 claims
- 1182US9073998B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofWEBER RICHARD·Filed 2009·Granted Jul 7, 2015·3 cites·88 claims
- 1281US11492411B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2019·Granted Nov 8, 2022·0 cites·20 claims
- 1381US10118968B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofWEBER RICHARD·Filed 2009·Granted Nov 6, 2018·2 cites·54 claims
- 1480US9085624B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofWEBER RICHARD·Filed 2008·Granted Jul 21, 2015·2 cites·26 claims
- 1580US8846873B2Antibodies directed to GPNMB and uses thereofXIAO FENG·Filed 2012·Granted Sep 30, 2014·9 cites·27 claims
- 1675US10508153B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2015·Granted Dec 17, 2019·1 cites·61 claims
- 1774US8101178B2Antibodies directed to tumor necrosis factor and uses thereofBABCOOK JOHN S·Filed 2007·Granted Jan 24, 2012·3 cites·21 claims
- 1855US2015044212A1Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1947US2016311919A1Antibodies Directed To GPNMB And Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2041US2005175999A1Methods for determining binding affinitiesFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →